Related Experiment Video
Updated: May 4, 2026
Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
Published on: August 2, 2022
The scope of nanoparticle therapies for future metastatic melanoma treatment
Francesca Baldelli Bombelli1, Carl A Webster2, Marc Moncrieff3
1School of Pharmacy, University of East Anglia, Norwich, Norfolk, UK; CEN-European Centre For Nanomedicine, C/O Dipartimento di Chimica, Materiali ed Ingegneria Chimica "Giulio Natta", Politecnico di Milano, Milan, Italy.
Abstract:
Metastatic melanoma is a highly aggressive malignancy that has traditionally been very difficult to treat. However, after decades of basic research into the signal transduction pathways that promote cancer cell survival, chemoresistance, growth, and crosstalk with the immune system, targeted therapies have now been developed that offer improved survival for patients with metastatic melanoma. Some of the most promising therapies that have been developed include ipilimumab, an anti-cytotoxic T lymphocyte antigen 4 antibody that enhances T-cell activity in the tumour, and selective BRAF inhibitors, such as vemurafenib that blocks tumour cell proliferation in patients with activating BRAF mutations. Although these treatments offer substantial hope for patients, they are not without their drawbacks, which include adverse side-effects, drug resistance, and eventual relapse. Nanotherapeutics holds significant promise to circumvent these shortcomings and has the additional advantage of potentially functioning as a diagnostic device. We will discuss the scope of the use of such multimodal nanoparticles for melanoma treatment and ask whether such particles can offer patients with metastatic melanoma improved prognoses for the future.
Insights
Targeted therapies like ipilimumab and BRAF inhibitors improve metastatic melanoma survival. Nanotherapeutics offer a promising approach to overcome treatment resistance and improve patient outcomes.
Area of Science:
- Oncology
- Immunology
- Nanotechnology
Background:
- Metastatic melanoma is an aggressive cancer with limited treatment options.
- Targeted therapies (ipilimumab, BRAF inhibitors) have improved survival but face challenges.
- Drug resistance, side effects, and relapse remain significant issues in melanoma treatment.
Purpose of the Study:
- To explore the potential of nanotherapeutics in treating metastatic melanoma.
- To discuss the advantages of multimodal nanoparticles for melanoma therapy and diagnostics.
- To evaluate if nanotherapeutics can improve prognoses for patients with metastatic melanoma.
Main Methods:
- Review of current targeted therapies for metastatic melanoma.
- Discussion of nanotherapeutic strategies and their mechanisms.
- Analysis of multimodal nanoparticles for combined therapeutic and diagnostic applications.
Main Results:
- Targeted therapies have shown promise but are limited by resistance and toxicity.
- Nanotherapeutics offer potential to overcome existing treatment limitations.
- Multimodal nanoparticles present a novel approach for integrated melanoma treatment and diagnosis.
Conclusions:
- Nanotherapeutics hold significant promise for overcoming challenges in metastatic melanoma treatment.
- Multimodal nanoparticles may offer improved prognoses and diagnostic capabilities for melanoma patients.
- Further research into nanotherapeutics is crucial for advancing melanoma care.
